Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05502367
Other study ID # ABI-2280-303
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 10, 2022
Est. completion date May 31, 2024

Study information

Verified date July 2023
Source Antiva Biosciences
Contact Oranee Daniels, MD
Phone 650-822-1400
Email odaniels@antivabio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of 3 dose escalating cohorts. Part B is a dose expansion cohort. Participants will self-administer ABI-2280.


Recruitment information / eligibility

Status Recruiting
Enrollment 29
Est. completion date May 31, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - Women, 25 to 55 years old. - For Part A, participants with biopsy-confirmed CIN (with visible lesions) regardless of p16 positivity may be enrolled upon consultation with PI and medical Monitor. These participants will not be required to get large loop excision of the transformation zone (LLETZ) if not medically necessary, as determined by the PI in consultation with the Medical Monitor. - For Part B, biopsy-confirmed cervical HSIL that is p16+ (p16INK4a expressed) within 60 days of enrollment (dosing) with no evidence of invasive cancer in any specimen. If biopsy was performed more than 60 days before planned enrollment, participants must agree to have another biopsy performed at the Screening visit, unless approved by the Medical Monitor. - No prior treatment for Cervical intraepithelial neoplasia (CIN). - Generally, in good health with no clinically significant pulmonary, cardiac, gastro-enterologic, neurologic, renal, musculoskeletal, rheumatologic, metabolic, neoplastic, or endocrine disease. Exclusion Criteria: - Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females. - Unwilling to use stringent methods of contraception (including barrier method, as well as another acceptable method) throughout the course of the study. - History of cancer, except basal cell or squamous cell carcinoma of the skin. - History of genital herpes with outbreak within prior 12 months. - Have an active pelvic or non-HPV (Human papillomavirus) vaginal infection (e.g., that was detected by a positive urine screen for gonorrhea or chlamydial infection, bimanual exam consistent with pelvic inflammatory disease, positive bedside testing criteria for bacterial vaginosis, candida vaginitis or trichomonal vaginitis, etc). - Current or recent abnormal vaginal discharge and /or abnormal vaginal bleeding. - Had a therapeutic abortion or miscarriage less than 3 months prior. - Any clinically significant immune suppressing condition. - Participants with a significant acute condition or any other condition that in the opinion of the Investigator might interfere with the evaluation of the study objectives. - Women who, in the PI's judgment, would be harmed by the delay in undergoing definitive treatment as a result of study participation and the ABI-2280 Vaginal Tablet dosing schedule.

Study Design


Intervention

Drug:
ABI-2280
Vaginal Tablet

Locations

Country Name City State
Australia East Sydney Doctors Darlinghurst New South Wales
Australia Gold Coast University Hospital Southport Queensland
South Africa Farmvos Bloemfontein Free State

Sponsors (1)

Lead Sponsor Collaborator
Antiva Biosciences

Countries where clinical trial is conducted

Australia,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events (Safety and Tolerability) For Parts A and B, to assess the safety and tolerability of ABI-2280 Vaginal Tablet by the incidence and severity of Adverse events (AEs). From Baseline to Day 42 post dose administration
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Time to maximum observed drug concentration (tmax) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Maximum observed drug concentration (Cmax) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Area under the curve (AUC) from time zero to last measurable concentration (AUC0-last) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses AUC from time zero to infinity (AUC8) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Apparent elimination half-life (t½) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Apparent terminal elimination rate constant (Kel) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Apparent clearance (CL/F) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Pharmacokinetics of ABI-2280 after single and multiple doses Apparent volume of distribution at the terminal phase (Vz/F) 60 minutes prior to dosing on Day 1, and 1 hour (± 5 mins) and 6 hours (± 1 hour) post-dose on Day 1. For Part A, additional samples will be taken at 2 hours (± 5 mins) and 24 hours (± 2 hours) post dose on Day 1.
Secondary Histopathologic changes in cHSIL by large loop excision of the transformation zone (LLETZ) specimen To assess histopathologic changes in cHSIL by LLETZ 12 weeks after the first dose of ABI-2280 Vaginal Tablet
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Completed NCT02907333 - Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia N/A
Recruiting NCT02576262 - HPV Integration Testing for Human Papillomavirus-Positive Women N/A
Completed NCT01029990 - Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program Phase 0
Recruiting NCT05078528 - Low-cost Imaging Technology for Global Prevention of Cervical Cancer N/A
Completed NCT02494310 - HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings N/A
Active, not recruiting NCT03429582 - Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device N/A
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Not yet recruiting NCT05510830 - Diagnostic Cervical Conization for Persistent Infection or Integration of HPV N/A
Completed NCT02237326 - Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women N/A
Completed NCT00316706 - Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Phase 3
Withdrawn NCT03143491 - Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) Phase 2
Completed NCT03293628 - Comparing Two Techniques of Haemostasis After Cervical Conization Phase 2
Recruiting NCT05266898 - Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Phase 4
Completed NCT02481414 - A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions Phase 2
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Recruiting NCT04646954 - DNA Methylation Testing for the Screening of Uterine Cervical Lesion Phase 3
Recruiting NCT04650711 - Immunohistochemical Staining of p16 for the Screening of Cervical Cancer Phase 2
Completed NCT01544478 - V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Phase 4
Completed NCT01735006 - Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine Phase 3